sector medic suppli devic
 anoth year sale growth
messag report full result tuesday line
earlier pre-announce includ organ revenu growth impress
sale howev oper leverag remain elus goal compani
underli gain off-set one-tim headwind stock continu
work believ manag need make good sale
growth guidanc target margin expans well see
achiev rais pt reiter buy rate
strong perform cap impress revenu
organ top consensu mark sixth consecut quarter
top line growth three compani oper segment provid upsid
rel street estim adjust ep came penni ahead
consensu qualiti somewhat poor ebita margin miss consensu
lower expect tax rate ad nickel earn full year ebita
contract one-tim headwind hurrican recal dilut
recent acquisit off-set underli leverag continu view
lack visibl oper leverag rare blemish otherwis clean stori
held stock back past year vs
share continu work believ manag need deliv
guidanc ebita leverag target includ acquisit
announc date see goal achiev combin anoth year
top line growth set bottom line gain
turn back quarter continu outperform knee mako
halo effect drive implant share gain fourth quarter orthoped sale rose
organ basi came street knee revenu
organ beat consensu continu take share quarter
sequenti yoy basi knee sale grew market
math difficult isol impact mako implant volum
factor zimmer on-going suppli constraint sens total
knee roll-out continu halo effect broader knee franchis
elsewher recon hip busi also saw sequenti acceler
sale organ beat consensu ou beat
offset modest miss world-wide hip growth acceler comp
tougher given momentum knee seem content stick
strategi hold hip side approach allow
overal recon franchis consist grow market round ortho divis
trauma extrem sale organ came consensu
driven broad strength foot ankl shoulder trauma segment
broader ortho market acceler need see smith nephew
result next week complet pictur estim global recon sale rose
constant currenc sell day adjust basi
intern revenu rise repres sharp acceler growth
despit yoy comp tougher extrem weather septemb
appear shift procedur final month year overal
estim underli growth slow meanwhil price
remain rel consist market share perspect zimmer
continu cede share result on-going suppli issu estim zimmer
lost ww recon share sequenti loss knee weigh stabl
share hip yoy basi zimmer lost ground
main beneficiari continu page
page analyst certif import disclosur
mako continu gain traction year total knee launch come
close system placement think quarter vs
still grew overal meanwhil continu make
solid progress upgrad exist instal base tka applic
 system access combin new placement estim
mako contribut sale ortho segment
organ fell shi elev street expect procedur number remain
robust howev nearli doubl back nearli total knee case
perform cours year importantli manag note
mako system sold competit account see
key indic technolog potenti drive increment implant share gain go
forward system instal hospit stryker
custom base mako continu long runway front even comp begin
get tougher move
elsewher medsurg continu deliv report medsurg sale
organ consensu strong perform
instrument medic account upsid medic organ
top reduc expect wake recal come
street driven strong growth core busi renew momentum
physio-control wake competitor qualiti issu busi
full product famili back work regain lost share manag
acknowledg disrupt recal custom elsewher instrument
organ contribut beat back continu
system roll-out final endoscopi organ miss consensu
sustain divis post revenu street
meanwhil neurotech continu enjoy solid momentum total neurotech
spine sale grew organ basi ahead consensu neuro
growth remain robust organ revenu top consensu
continu enjoy strong momentum across hemorrhag ischem
neurosurgeri power tool product portfolio fourth quarter strength
dilut spine organ turn slightli posit beat
street estim continu struggl remain challeng
market expect underli market soft persist forese futur
place premium innov technolog differenti competitor stryker
recent announc deal acquir france-bas vexim fit mold view albeit
rel small scale sale
top line lower expect tax rate boost earn stryker
gross margin came shi consensu driven unfavor mix price
eros disrupt compani puerto rico manufactur facil sg
spend increas yoy sale consensu
meanwhil spend grew yoy sale
street collect result ebita margin yoy
street estim combin impact weather novadaq
integr estim ebita quarter without ebita
margin would expand quarter full year despit
impress top line perform past quarter visibl margin leverag
remain elus target manag expect chang cfo
glenn boehnlein guid ebita expans inclus dilut recent
acquisit final lower effect tax rate vs consensu ad
roughli adjust ep
page analyst certif import disclosur
adjust estim model call ep sale
organ compar previou estim
respect tougher comp rise mako expect return
normalci zimmer could eventu make life tougher view compani
guidanc achiev believ compani current top line momentum
support premium valuat rais price target
base previous multipl revis forward ntm
ep estim signific upsid potenti target current level
reiter buy rate
page analyst certif import disclosur
diversifi busi model posit sustain revenu growth high
end large-cap group follow recent deal activ strengthen medic
segment compani seven differ busi contribut overal revenu
one franchis respons uniqu model insul
temporari weak one segment allow cast wide net
potenti valu creat acquisit result one consist
top line growth stori large-cap med-tech past year expect
continu go forward drive sustain ep growth potenti faster
gain execut around margin leverag improv deploy balanc
sheet capac net debt/ebitda today product manner believ profil
warrant premium valuat rel peer
share current trade ntm ep estim ntm
ebitda premium large-cap med-tech averag ntm ep
ntm ebitda believ superior growth profil peg
top bottom line vs group averag warrant
premium valuat rais price target base
previous multipl forward ntm ep estim
signific upsid potenti target current level assign stryker buy
downsid risk rate price target includ disappoint ramp mako
total knee applic increas price and/or volum pressur ortho implant
manufactur govern initi contain healthcar cost legal payout
patent product liabil case exceed estim slowdown hospit
capit equip spend could neg impact stryker medsurg growth
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
